We've developed a new patient-derived model of a rare cancer, TFCP2-rearranged intraosseous rhabdomyosarcoma, and validated a promising preclinical treatment approach for this disease.
doi.org/10.1158/1535...
We've developed a new patient-derived model of a rare cancer, TFCP2-rearranged intraosseous rhabdomyosarcoma, and validated a promising preclinical treatment approach for this disease.
doi.org/10.1158/1535...
www.ozmrs.com/committee
www.ozmrs.com/committee
Thank you @garvaninstitute.bsky.social for the outfits!